SHARE:  
Dear Investors,
We are glad to introduce a new drug license out asset CD22 + CD37 CAR-T for Hematological malignancies (leukemia, multiple myeloma, lymphoma). The asset is looking for out-licensing or co-development. 
Here are the details, please contact us if you are interested.
Glad to have you aboard. We encourage you to reply this email directly if you have any license in or out requests.
 
Best regards
The bioSeedin Team

Support email


Get Social
ABOUT US
bioSeedin is dedicated to building a communication and knowledge service platform for biopharmaceuticals companies. Based on the client's resources of nearly 6000 pharmaceutical enterprises around the world, we are also the cooperation and trading platform of licensing business which can help you find the license in and out business faster. Our team has rich experience in target drugs in a wide range of therapeutic areas including oncology, rheumatology, immunology, respiratory, anesthesia, gastroenterology, and endocrinology.